Recce Pharmaceuticals Ltd
OTC:RECEF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Recce Pharmaceuticals Ltd (RECEF) under the Base Case is 0.37 USD per share.
Compared with the current market price of 0.22 USD, the stock appears
Undervalued by 41% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Recce Pharmaceuticals Does
Recce Pharmaceuticals is an Australian drug-development company focused on new treatments for serious infections. Its main work is to design and test synthetic anti-infective drugs aimed at bacteria, viruses, and fungi, especially infections that are hard to treat with existing medicines. The company is still in development mode, so it does not sell a broad portfolio of approved drugs like a big pharma company would.
- Headquarters
- Australia AU
- IPO date
- Jan 15, 2016
Balance Sheet
Continue RECEF Research
Decided on Recce Pharmaceuticals? Get an email when RECEF reaches the price you’d buy at. Free with an account.
Other Recce Pharmaceuticals listings
What is the Intrinsic Value of one RECEF stock?
The intrinsic value for
Recce Pharmaceuticals Ltd (RECEF) under the Base Case is 0.37 USD.
Is RECEF stock undervalued or overvalued?
Compared with the current market price of 0.22 USD, the stock appears Undervalued by 41% .